| Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia 2009 · CoQ10 group · Women at increased risk of pre-eclampsia during pregnancy | 200 mg | — | 118 |
| Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction 2003 · CoQ group (group A) · Patients after acute myocardial infarction; age and sex not reported | 120 mg | 1 year | 73 |
| Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction 1998 · intervention group A · Patients with acute myocardial infarction; age and sex not specified | 120 mg | 4 weeks | 73 |
| Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting 1994 · group 1 · Patients undergoing elective coronary artery bypass grafting | 150 mg | 7 days | — |
| Reduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens 2015 · Active treatment · Elderly Swedish community-dwelling adults; mean age 78 years; men and women; described as healthy, with low baseline selenium status | 200 mg | 4 years | 221 |
| Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly 2018 · Active treatment group · Elderly healthy Swedish community-dwelling adults; mean age 78 years, men and women | 200 mg | 1461 days | 221 |
| Supplementation with Selenium and Coenzyme Q10 Reduces Cardiovascular Mortality in Elderly with Low Selenium Status. A Secondary Analysis of a Randomised Clinical Trial 2016 · active treatment group · Adults aged 70–80 years in Sweden, without a stated requirement for a diagnosed condition; participants were analysed in strata by baseline serum selenium concentration. | 200 mg | 4 years | 219 |
| The clinical outcome of Montelukast versus co-enzyme Q10 in adult patients with sepsis: A randomized controlled clinical trial 2026 · CoQ10 · Adults with sepsis | 210 mg | — | 30 |
| Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial 2006 · 300 mg dose · healthy adult volunteers | 300 mg | 4 weeks | — |
| The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial 2014 · CoQ10 group · Adults with moderate to severe chronic heart failure | 300 mg | 2 years | — |
| Discovering the Potential Value of Coenzyme Q10 as an Adjuvant Treatment in Patients With Depression 2024 · CoQ10 group · Patients with moderate or severe depression; age and sex not reported | 200 mg | 8 weeks | 36 |
| Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study 2019 · CoQ10 group · Adults aged 18 years or older, either sex, with dyslipidemia inadequately controlled on statins and statin intolerance | 100 mg | 90 days | 30 |
| The effects of coenzyme Q10 supplementation on metabolic profiles and parameters of mental health in women with polycystic ovary syndrome 2022 · CoQ10 group · Women aged 18–40 with polycystic ovary syndrome | 100 mg | 12 weeks | 28 |
| Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study 2014 · Q10 group · Adults aged 40–65 of both sexes with mild-to-moderate statin-related muscle pain | 100 mg | 30 days | 25 |
| Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress 2014 · coQ10 group · Adults with nonalcoholic fatty liver disease | 100 mg | 4 weeks | 22 |
| Water-soluble coenzyme Q10 formulation (Q-TER(®)) in the treatment of presbycusis 2010 · Group A · Patients with presbycusis; age and sex not reported | 160 mg | 30 days | 20 |
| Noninvasive instrumental evaluation of coenzyme Q(10) phytosome on endothelial reactivity in healthy nonsmoking young volunteers: A double-blind, randomized, placebo-controlled crossover clinical trial 2022 · CoQ10 phytosome · Healthy nonsmoking volunteers aged 18–40 years | 150 mg | 4 weeks | 20 |
| Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction 2008 · fenofibrate + CoQ · Adults aged 40–79 years with type 2 diabetes and left ventricular diastolic dysfunction | 200 mg | 26 weeks | 19 |
| Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins 2012 · CoQ10 treatment · Athletes aged 50 years or older taking stable doses of statins | 200 mg | 6 weeks | 19 |
| Effects of Coenzyme Q10 Supplementation on Physical Function Adaptations to High-Intensity Interval Training in Older Adults 2025 · HIIT + CoQ10 · Healthy, sedentary adults aged 65–75 years; 22 men and 16 women enrolled across the study | 100 mg | 8 weeks | 19 |
| Effect of coenzyme q10 on myopathic symptoms in patients treated with statins 2007 · coenzyme Q10 · Patients with statin-associated myopathic symptoms | 100 mg | 30 days | 18 |
| Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction 2008 · CoQ · Adults aged 40–79 years with type 2 diabetes and left ventricular diastolic dysfunction | 200 mg | 26 weeks | 16 |
| The monitoring role of otoacoustic emissions and oxidative stress markers in the protective effects of antioxidant administration in noise-exposed subjects: a pilot study 2009 · Q-Ter group · Normal volunteers exposed to noise, at risk of sound-induced cochlear damage | 200 mg | 7 days | 10 |
| Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes 2003 · CoQ · Adults with dyslipidaemic type 2 diabetes | 200 mg | 12 weeks | — |
| Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes 2003 · Fenofibrate plus CoQ · Adults with dyslipidaemic type 2 diabetes | 200 mg | 12 weeks | — |
| Antifatigue effects of coenzyme Q10 during physical fatigue 2008 · 100 mg/d coenzyme Q10 group · healthy volunteers | 100 mg | 8 days | — |
| Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial 2009 · coenzyme Q(10) · Men aged 27–39 with idiopathic asthenozoospermia | 200 mg | 26 weeks | — |
| Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients 2009 · oral CoQ10 · Adults aged 40–79 with type 2 diabetes, on stable-dose statin therapy, and endothelial dysfunction | 200 mg | 12 weeks | — |
| Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial 2011 · CoQ10 group · Infertile men with idiopathic oligoasthenoteratozoospermia | 200 mg | 12 weeks | — |
| Coenzyme Q10 benefits symptoms in Gulf War veterans: results of a randomized double-blind study 2014 · Q100 · Gulf War veterans with Gulf War illness; ages and sex distribution not specified | 100 mg | 15 weeks | — |
| Effect of Coenzyme Q10 on Oxidative Stress, Glycemic Control and Inflammation in Diabetic Neuropathy: A Double Blind Randomized Clinical Trial 2014 · CoQ10 · Patients with type 2 diabetes and neuropathic signs | 200 mg | 12 weeks | — |
| The effect of dietary intake of coenzyme Q10 on skin parameters and condition: Results of a randomised, placebo-controlled, double-blind study 2017 · 150 mg CoQ10 · Healthy subjects; age and sex not reported | 150 mg | 12 weeks | — |
| Evaluating the Effect of Coenzyme Q10 Augmentation on Treatment of Bipolar Depression: A Double-Blind Controlled Clinical Trial 2018 · adjuvant CoQ10 group · Patients with bipolar disorder experiencing a current depressive episode | 200 mg | 8 weeks | — |
| Impact of Coenzyme Q10 and Selenium on Seminal Fluid Parameters and Antioxidant Status in Men with Idiopathic Infertility 2021 · CoQ10 · Men with idiopathic oligoasthenoteratospermia | 200 mg | 90 days | — |
| Effect of coenzyme Q10 on post-extraction tissue healing in wisdom tooth Surgery: double-blind randomized clinical trial 2025 · CoQ10 group · People undergoing wisdom tooth extraction; age and sex not stated | 100 mg | 30 days | — |
| Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study 1993 · coenzyme Q10 · Adults aged 26–89 years with chronic congestive heart failure, NYHA functional class III or IV, receiving conventional heart-failure treatment | 2 mg/kg | 1 year | 319 |
| Improved cardiovascular health by supplementation with selenium and coenzyme Q10: applying structural equation modelling (SEM) to clinical outcomes and biomarkers to explore underlying mechanisms in a prospective randomized double-blind placebo-controlled intervention project in Sweden 2022 · Active treatment group · Adults aged 70–88 years with low selenium status and age-related low coenzyme Q10 levels | 200 mg | 4 years | 221 |
| Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study 2018 · CoQ10 plus TMZ group · Adults aged 18 years or older, male or female, with coronary heart disease and renal insufficiency undergoing elective cardiac catheterization | 60 mg | 6 days | 75 |
| Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial 2006 · 600 mg dose · healthy adult volunteers | 600 mg | 4 weeks | — |
| Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial 2006 · 900 mg dose · healthy adult volunteers | 900 mg | 4 weeks | — |
| Improved Health-Related Quality of Life, and More Days out of Hospital with Supplementation with Selenium and Coenzyme Q10 Combined. Results from a Double Blind, Placebo-Controlled Prospective Study 2015 · active substance group · community-dwelling elderly adults; mean age 77 years; 51% male | 200 mg | 1461 days | 221 |
| Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study 2010 · CoQ(10) group · Patients with early chronic Peyronie's disease; age and sex not specified | 300 mg | 24 weeks | 93 |
| [L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: A double-blind randomized controlled trial] 2018 · CoQ10 group · Men with idiopathic oligoasthenozoospermia | 60 mg | 90 days | 63 |
| Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial 2022 · CoQ10 + pregabalin · Patients with painful diabetic neuropathy; age and sex not reported | 300 mg | 8 weeks | 57 |
| Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease 2003 · CoQ(10) supplementation · Adults with treated and stable Parkinson's disease | 360 mg | 4 weeks | 28 |
| The effect of coenzyme Q10 on the exercise performance of cross-country skiers 1997 · Coenzyme Q10 supplementation · Finnish top-level cross-country skiers; age and sex not specified | 90 mg | — | 25 |
| The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study 2012 · ubiquinone · Adults with type 2 diabetes and diabetic polyneuropathy; mean age 56 years | 400 mg | 12 weeks | 24 |
| Coenzyme Q10 and exercise training in chronic heart failure 2006 · oral CoQ(10) · Adults with stable NYHA class II or III chronic heart failure secondary to ischaemic heart disease; mean age 59 years; 20 men and 3 women | 300 mg | 4 weeks | 23 |
| Coenzyme Q10 and exercise training in chronic heart failure 2006 · CoQ(10) plus supervised exercise training (ET) · Adults with stable NYHA class II or III chronic heart failure secondary to ischaemic heart disease; mean age 59 years; 20 men and 3 women | 300 mg | 4 weeks | 23 |
| Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers 2019 · CoQ10 · Non-menopausal women aged 18–50 with episodic migraine | 400 mg | 90 days | 23 |
| Acute effects of MitoQ on vascular endothelial function are influenced by cardiorespiratory fitness and baseline FMD in middle-aged and older adults 2024 · MitoQ · Middle-aged and older adults aged 45 years or older, including exercisers and non-exercisers | 80 mg | 1 day | 23 |
| Role for a water-soluble form of CoQ10 in female subjects affected by fibromyalgia. A preliminary study 2017 · CoQ10 administration · 22 female subjects with a diagnosis of fibromyalgia | 400 mg | — | 22 |
| Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial 2005 · CoQ10 · Migraine patients | 300 mg | 90 days | 21 |
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline 2002 · coenzyme Q10 300 mg/d group · People with early Parkinson disease who did not require treatment for their disability; age and sex not reported | 300 mg | 487 days | — |
| Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study 2004 · Ultrasome--CoQ10 · Patients with end-stage heart failure awaiting heart transplantation | 60 mg | 90 days | — |
| Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases 1991 · ubidecarenone-treated patients · Patients with chronic obstructive pulmonary disease participating in an exercise training program | 50 mg | — | — |
| Antifatigue effects of coenzyme Q10 during physical fatigue 2008 · 300 mg/d coenzyme Q10 group · healthy volunteers | 300 mg | 8 days | — |
| Can coenzyme q10 improve clinical and molecular parameters in fibromyalgia? 2013 · CoQ10 supplementation · Patients with fibromyalgia | 300 mg | 40 days | — |
| Coenzyme Q10 benefits symptoms in Gulf War veterans: results of a randomized double-blind study 2014 · Q300 · Gulf War veterans with Gulf War illness; ages and sex distribution not specified | 300 mg | 15 weeks | — |
| The effect of dietary intake of coenzyme Q10 on skin parameters and condition: Results of a randomised, placebo-controlled, double-blind study 2017 · 50 mg CoQ10 · Healthy subjects; age and sex not reported | 50 mg | 12 weeks | — |
| Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease 1999 · Coenzyme Q10 (group A) · Patients with essential hypertension and coronary artery disease receiving antihypertensive medication | 120 mg | 8 weeks | 30 |
| The Effects of Coenzyme Q10 Supplementation on Glucose Metabolism, Lipid Profiles, Inflammation, and Oxidative Stress in Patients With Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial 2018 · CoQ10 group · People with diabetic nephropathy; age and sex not specified | 100 mg | 12 weeks | 25 |
| Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension 2001 · CoQ-treated group · Men and women with isolated systolic hypertension; ages not stated | 120 mg | 12 weeks | — |
| Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes 2002 · CoQ alone · Adults with uncomplicated type 2 diabetes and dyslipidaemia | 200 mg | 12 weeks | — |
| Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes 2002 · CoQ plus fenofibrate · Adults with uncomplicated type 2 diabetes and dyslipidaemia | 200 mg | 12 weeks | — |
| The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial 2009 · CoQ · Nondiabetic patients with stage 3–4 chronic kidney disease | 200 mg | 8 weeks | — |
| The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients 2013 · Q10 group · Adults with type 2 diabetes; age and sex not specified | 200 mg | 12 weeks | — |
| Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals 2018 · CoQ10 · Dyslipidemic subjects; age and sex not specified | 120 mg | 24 weeks | — |
| Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial 2018 · CoQ10 treatment (study group) · Women younger than 35 years with poor ovarian response and diminished ovarian reserve (AMH <1.2 ng/ml and AFC <5) undergoing ART | 600 mg | 60 days | 76 |
| Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease 2023 · CoQ10 · Adults aged 30–79 with chronic kidney disease (eGFR below 60 mL/min/1.73 m²) and 6-minute walking distance below 550 m | 1.2 g | 6 weeks | 25 |
| Mitochondria-targeted antioxidant supplementation improves 8 km time trial performance in middle-aged trained male cyclists 2021 · MitoQ supplementation · Healthy, recreationally trained male cyclists aged 44 ± 4 years | 20 mg | 4 weeks | 19 |
| MitoQ supplementation augments acute exercise-induced increases in muscle PGC1α mRNA and improves training-induced increases in peak power independent of mitochondrial content and function in untrained middle-aged men 2022 · MitoQ group · Healthy untrained middle-aged men, mean age 44 years; free of chronic illness and not selected for a diagnosed condition | 20 mg | 31 days | 12 |
| Royal jelly plus coenzyme Q10 supplementation improves high-intensity interval exercise performance via changes in plasmatic and salivary biomarkers of oxidative stress and muscle damage in swimmers: a randomized, double-blind, placebo-controlled pilot trial 2022 · RJQ group · Male high-level swimmers, approximately 19 years old, with at least Candidate Master of Sports or Master of Sports rank | 60 mg | 10 days | 10 |
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline 2002 · coenzyme Q10 600 mg/d group · People with early Parkinson disease who did not require treatment for their disability; age and sex not reported | 600 mg | 487 days | — |
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline 2002 · coenzyme Q10 1200 mg/d group · People with early Parkinson disease who did not require treatment for their disability; age and sex not reported | 1.2 g | 487 days | — |
| Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma 2005 · Antioxidants in addition to standard antiasthmatic therapy · Adults aged 25–50 with persistent mild to moderate bronchial asthma | 120 mg | 16 weeks | — |
| Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function: the FAITH randomized clinical trial 2013 · AGE/CoQ10 · Asymptomatic Los Angeles County firefighters with intermediate cardiovascular risk and high occupational stress | 120 mg | 1 year | — |
| Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial 2015 · Verum (investigational nutritional product) · Adults aged 18–65 of either sex with migraine with or without aura, and at least 3 migraine attacks per month before recruitment | 150 mg | 90 days | 63 |
| Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial 2021 · CoQ10 + NADH group · Adult women with ME/CFS, aged 18 years or older | 200 mg | 8 weeks | 72 |
| [L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: A double-blind randomized controlled trial] 2018 · Combination group · Men with idiopathic oligoasthenozoospermia | 60 mg | 90 days | 63 |
| Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study 2011 · Q-ter + creatine group · Patients with stable chronic heart failure secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ≤35%) | 320 mg | 8 weeks | 35 |
| Protective effect of anti-oxidants on endothelial function in young Korean-Asians compared to Caucasians 2012 · antioxidant vitamins · Healthy Korean and Caucasian adults aged 20–35 years | 300 mg | 2 weeks | 20 |
| Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients 2009 · EP1 · Patients with severe erythrodermic psoriasis | 50 mg | 30 days | — |
| Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients 2009 · PsA1 · Patients with severe arthropathic psoriasis | 50 mg | 5 weeks | — |
| Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? 2015 · CoQ10 plus NADH group · Spanish patients with chronic fatigue syndrome; age and sex not reported | 200 mg | 8 weeks | — |
| The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease 2015 · combination therapy · Patients with Parkinson's disease and mild cognitive impairment; age and sex not specified | 300 mg | 548 days | — |
| The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial 2019 · Coenzyme Q10 and L-carnitine group · Men and women aged 20–40 years with migraine headache | 30 mg | 8 weeks | — |
| Coenzyme Q10 in patients undergoing CABG: Effect of statins and nutritional supplementation 2008 · CoQ(10) supplementation · Adults with left ventricular dysfunction undergoing CABG; age and sex not reported | 150 mg | 4 weeks | 40 |
| Women have higher levels of CoQ(10) than men when supplemented with a single dose of CoQ(10) with monoglycerides omega-3 or rice oil and followed for 48 h: a crossover randomised triple blind controlled study 2022 · CoQ10 alone · Healthy men and women aged 18–50 years | 200 mg | 1 day | 30 |
| Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study 2007 · CoQ10 group · Hypercholesterolemic patients treated with atorvastatin | 100 mg | 16 weeks | 24 |
| Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals 2020 · Standard product (SP) · Healthy adults aged 65 years or older, women and men | 100 mg | 1 day | 21 |
| Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals 2020 · Investigational product (IP) · Healthy adults aged 65 years or older, women and men | 100 mg | 1 day | 21 |
| Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease 2012 · Q10-150 group · Patients with coronary artery disease, including people with at least 50% stenosis of one major coronary artery or who had received percutaneous transluminal coronary angioplasty | 150 mg | 12 weeks | 18 |
| Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease 2012 · Q10-150 group · Patients with coronary artery disease | 150 mg | 12 weeks | 18 |
| Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolemic young adults 2000 · CoQ(10) · Healthy adults with hypercholesterolemia and endothelial dysfunction at baseline; mean age 34 years (SD 10), nine women and three men | 150 mg | 4 weeks | 12 |
| Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men 2018 · ubiquinone supplement · older men; age range and health condition not reported | 200 mg | 2 weeks | 10 |
| Myocardial preservation by therapy with coenzyme Q10 during heart surgery 1993 · CoQ10 group · High-risk patients undergoing heart surgery with blood CoQ10 deficiency, low cardiac index, and low left ventricular ejection fraction | 100 mg | 44 days | 10 |
| Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study 2003 · 100 mg Q10 group · healthy men | 100 mg | 60 days | — |
| Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men 2005 · 200 mg coenzyme Q10 group · healthy men aged 18–55 years | 200 mg | 20 days | — |
| Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men 2005 · divided-dose 2 × 100 mg coenzyme Q10 group · healthy men aged 18–55 years | 200 mg | 20 days | — |
| Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men 2005 · 100 mg coenzyme Q10 group · healthy men aged 18–55 years | 100 mg | 20 days | — |
| Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men 2005 · 100 mg crystalline coenzyme Q10 group · healthy men aged 18–55 years | 100 mg | 20 days | — |
| Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system 2009 · colloidal-Q10 · healthy adult men and women; age range not reported | 120 mg | 1 day | — |
| Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system 2009 · solubilizate 1 · healthy adult men and women; age range not reported | 120 mg | 1 day | — |
| Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system 2009 · oil-based formulation · healthy adult men and women; age range not reported | 120 mg | 1 day | — |
| Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system 2009 · solubilizate 2 · healthy adult men and women; age range not reported | 120 mg | 1 day | — |
| Effect of Coenzyme Q10 supplementation on antioxidant enzymes activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial 2014 · CoQ10 group · men with idiopathic oligoasthenoteratozoospermia (OAT) | 200 mg | 90 days | — |
| Effects of 12 Weeks of Essential Amino Acids (EAA)-Based Multi-Ingredient Nutritional Supplementation on Muscle Mass, Muscle Strength, Muscle Power and Fatigue in Healthy Elderly Subjects: A Randomized Controlled Double-Blind Study 2019 · multi-ingredient nutritional supplement (SUPP) · Healthy men and women aged 65–80 years, not selected for a diagnosed disease; the group was described as non-sarcopenic and well-nourished | 100 mg | 12 weeks | 19 |
| Coenzyme Q10 supplementation improves cholesterol efflux capacity and antiinflammatory properties of high-density lipoprotein in Chinese adults with dyslipidemia 2022 · CoQ10 group · Adults with dyslipidemia | 120 mg | 24 weeks | 51 |
| Effect of Coenzyme Q(10) on Insulin Resistance in Korean Patients with Prediabetes: A Pilot Single-Center, Randomized, Double-Blind, Placebo-Controlled Study 2018 · experimental group · Adults aged 20–65 with impaired glucose tolerance (prediabetes) | 200 mg | 8 weeks | 40 |
| Effects of Coenzyme Q10 Supplementation on Serum Values of Gamma-glutamyl transferase, Pseudocholinesterase, Bilirubin, Ferritin, and High-Sensitivity C-Reactive Protein in Women with Type 2 Diabetes 2019 · drug group · Women with type 2 diabetes | 100 mg | 12 weeks | 36 |
| Effects of coenzyme Q10 supplementation on serum values of adiponectin, leptin, 8-isoprostane and malondialdehyde in women with type 2 diabetes 2018 · drug group · women with type 2 diabetes mellitus | 100 mg | 12 weeks | 34 |
| Reduction in asymmetric dimethylarginine plasma levels by coenzyme Q10 supplementation in patients with type 2 diabetes mellitus 2015 · CoQ10 group · Adults with type 2 diabetes mellitus | 200 mg | 12 weeks | 31 |
| The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome 2016 · Group A · Overweight or obese adults aged 40–85 with type 2 diabetes and coronary heart disease, described as having metabolic syndrome | 100 mg | 8 weeks | 30 |
| The Effect of Coenzyme Q10 Supplementation on Pro-Inflammatory Factors and Adiponectin in Mildly Hypertensive Patients: A Randomized, Double-Blind, Placebo-Controlled Trial 2015 · coenzyme Q10 (QG) · mildly hypertensive patients; age and sex not reported | 100 mg | 12 weeks | 30 |
| The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial 2017 · CoQ10 supplements · Women diagnosed with polycystic ovary syndrome (PCOS) | 100 mg | 12 weeks | 30 |
| Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients 2018 · CoQ10 group · Diabetic patients receiving hemodialysis; age and sex not specified | 120 mg | 12 weeks | 30 |
| Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial 2019 · CoQ10 · Adults aged 18–56 years with rheumatoid arthritis diagnosed at least 6 months earlier and DAS-28 > 3.2 | 100 mg | 60 days | 27 |
| Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role 1999 · coenzyme Q10 group · People with acute coronary disease (acute myocardial infarction, unstable angina, or angina pectoris) and moderately raised lipoprotein(a) | 120 mg | 4 weeks | 25 |
| Effects of Coenzyme Q10 Supplementation on Inflammatory Cytokines (TNF-α, IL-6) and Oxidative Stress in Rheumatoid Arthritis Patients: A Randomized Controlled Trial 2015 · CoQ10 group · Patients with rheumatoid arthritis | 100 mg | 60 days | 22 |
| The effect of coenzyme Q10 supplementation on inflammatory and endothelial dysfunction markers in overweight/obese polycystic ovary syndrome patients 2021 · CoQ10 group · Overweight and obese women diagnosed with polycystic ovary syndrome | 200 mg | 8 weeks | 22 |
| Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study 1999 · 180 mg/day Q10 group · Volunteers vaccinated against hepatitis B; age and sex not reported | 180 mg | 90 days | 21 |
| n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease 2016 · CoQ · Men and women aged 25–75 years with chronic renal impairment (eGFR >15 and <60 mL/min/1.73 m²) | 200 mg | 8 weeks | 21 |
| Coenzyme Q10 consumption promotes ABCG1-mediated macrophage cholesterol efflux: a randomized, double-blind, placebo-controlled, cross-over study in healthy volunteers 2015 · CoQ10 · healthy volunteers | 200 mg | 7 days | 20 |
| The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome 2018 · CoQ10 group · Women with diagnosed polycystic ovary syndrome (PCOS) | 100 mg | 12 weeks | 20 |
| Effects of Coenzyme Q10 Supplementation on Gene Expressions Related to Insulin, Lipid, and Inflammation Pathways in Patients With Diabetic Nephropathy 2018 · Coenzyme Q10 group · Adults aged 40 to 85 with diabetic nephropathy | 100 mg | 12 weeks | 20 |
| Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo 1998 · Ubiquinone supplementation with lovastatin · Men with coronary heart disease and hypercholesterolemia | 180 mg | 6 weeks | 19 |
| Oxidative stress and antioxidant defense in plasma after repeated bouts of supramaximal exercise: the effect of coenzyme Q10 2011 · CoQ10 · Healthy, sedentary men | 100 mg | 8 weeks | 15 |
| Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study 2000 · Q10 group · Subjects with mild hypercholesterolemia undergoing statin treatment | 200 mg | 90 days | — |
| Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study 2004 · Coenzyme Q group · HIV-infected patients, including people with lipodystrophy, peripheral neuropathy or neither, and healthy control subjects | 200 mg | 90 days | — |
| The protective role of coenzyme Q10 in renal injury associated with extracorporeal shockwave lithotripsy: a randomised, placebo-controlled clinical trial 2014 · CoQ10 group · Patients with renal lithiasis undergoing extracorporeal shockwave lithotripsy (ESWL) | 200 mg | 2 weeks | — |
| A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease 2016 · Coenzyme Q10 · Patients with chronic kidney disease; age and sex not specified. | 200 mg | 8 weeks | — |
| n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease 2015 · CoQ · Patients with chronic kidney disease | 200 mg | 8 weeks | — |
| Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial 2016 · CoQ10 group · Patients with nonalcoholic fatty liver disease (age and sex not specified) | 100 mg | 12 weeks | — |
| The Effect of Coenzyme Q10 Supplementation on Circulating Levels of Novel Adipokine Adipolin/CTRP12 in Overweight and Obese Patients with Type 2 Diabetes 2017 · Q10 group · Overweight and obese patients with type 2 diabetes | 200 mg | 12 weeks | — |
| The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease 2018 · CoQ · Patients with chronic kidney disease (CKD) | 200 mg | 8 weeks | — |
| Coenzyme Q10 improves the survival and reduces inflammatory markers in septic patients 2020 · CoQ10 group · Septic patients; age and sex not specified | 200 mg | 7 days | — |
| A randomized controlled trial on the coloprotective effect of coenzyme Q10 on immune-inflammatory cytokines, oxidative status, antimicrobial peptides, and microRNA-146a expression in patients with mild-to-moderate ulcerative colitis 2021 · CoQ10 group · Patients with mild-to-moderate ulcerative colitis in remission; age and sex not specified | 200 mg | 8 weeks | — |
| Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping 1996 · group I · Patients undergoing elective vascular surgery for abdominal aortic aneurysm or obstructive aorto-iliac disease | 150 mg | 7 days | — |
| The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial 2009 · both supplements · Nondiabetic patients with stage 3–4 chronic kidney disease | 200 mg | 8 weeks | — |
| Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome 2018 · treatment group · Adults with metabolic syndrome who had hypertension and hypercholesterolemia; mean age 57.4 years | 30 mg | 60 days | — |
| Increase in insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 after supplementation with selenium and coenzyme Q10. A prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens 2017 · active treatment · Elderly healthy Swedish adults, mean age about 76 years; both sexes; some had hypertension, ischemic heart disease, or diabetes | 200 mg | 1461 days | 117 |
| Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue 2005 · coenzyme Q(10) · Patients undergoing elective cardiac surgery | 300 mg | 2 weeks | 62 |
| Coenzyme Q10 supplementation in acute ischemic stroke: Is it beneficial in short-term administration? 2020 · CoQ10-supplemented group · Patients with acute ischemic stroke; age and sex not specified | 300 mg | 4 weeks | 30 |
| Women have higher levels of CoQ(10) than men when supplemented with a single dose of CoQ(10) with monoglycerides omega-3 or rice oil and followed for 48 h: a crossover randomised triple blind controlled study 2022 · CoQ10 + rice oil · Healthy men and women aged 18–50 years | 200 mg | 1 day | 30 |
| Comparative bioavailability of two novel coenzyme Q10 preparations in humans 2003 · fast-melting tablet · adult male subjects; age and health status not reported | 60 mg | 1 day | 24 |
| Comparative bioavailability of two novel coenzyme Q10 preparations in humans 2003 · effervescent tablet · adult male subjects; age and health status not reported | 60 mg | 1 day | 24 |
| Comparative bioavailability of two novel coenzyme Q10 preparations in humans 2003 · soft gelatin preparation · adult male subjects; age and health status not reported | 60 mg | 1 day | 24 |
| Comparative bioavailability of two novel coenzyme Q10 preparations in humans 2003 · powder-filled hard-shell preparation · adult male subjects; age and health status not reported | 60 mg | 1 day | 24 |
| Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease 2012 · Q10-60 group · Patients with coronary artery disease, including people with at least 50% stenosis of one major coronary artery or who had received percutaneous transluminal coronary angioplasty | 60 mg | 12 weeks | 19 |
| Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease 2012 · Q10-60 group · Patients with coronary artery disease | 60 mg | 12 weeks | 19 |
| Relative bioavailability and antioxidant potential of two coenzyme q10 preparations 2003 · BT-CoQ10 · 11 healthy individuals | 300 mg | 7 days | 11 |
| Relative bioavailability and antioxidant potential of two coenzyme q10 preparations 2003 · Commercial grade CoQ10 · 11 healthy individuals | 300 mg | 7 days | 11 |
| Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets 2003 · Group I · Healthy men aged 19–23 years | 50 mg | 15 days | 10 |
| Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets 2003 · Group II · Healthy men aged 19–23 years | 50 mg | 15 days | 10 |
| Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy 2017 · commercial-grade CoQ10 powder (solid formulation) · Six healthy individuals; ages and sex not specified | 250 mg | 7 days | 6 |
| Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy 2017 · oil-in-water liquid emulsion · Six healthy individuals; ages and sex not specified | 250 mg | 7 days | 6 |
| Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10) 2006 · Solu Q10 solubilizate formulation · Healthy volunteers; age and sex not specified | 60 mg | 2 weeks | — |
| Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10) 2006 · Other solubilizate formulations · Healthy volunteers; age and sex not specified | 60 mg | 2 weeks | — |
| Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10) 2006 · Oily dispersion formulations · Healthy volunteers; age and sex not specified | 60 mg | 2 weeks | — |
| Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10) 2006 · Crystalline CoQ10 formulation · Healthy volunteers; age and sex not specified | 60 mg | 2 weeks | — |
| Selenoprotein P increases upon selenium and coenzyme Q(10) supplementation and is associated with telomere length, quality of life and reduced inflammation and mortality 2024 · selenium yeast and coenzyme Q 10 supplementation · elderly community-living participants with low selenium status | 200 mg | 4 years | — |
| Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial 2015 · Combination A · Adults aged 18–70 with hypercholesterolemia not requiring statins or statin-intolerant | 2 mg | 4 weeks | 23 |
| Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study 2019 · Nutraceutical combination · Adults aged 18–70 with low cardiovascular risk, in primary cardiovascular prevention, and LDL-C of 130–200 mg/dL | 20 mg | 12 weeks | 16 |
| Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study 2017 · Body Lipid (BL) · Adults aged 18–75, both sexes, with mild-to-moderate hypercholesterolemia | 2 mg | 4 weeks | — |
| Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study 2017 · Armolipid Plus (AM) · Adults aged 18–75, both sexes, with mild-to-moderate hypercholesterolemia | 2 mg | 4 weeks | — |
| Levels of sP-selectin and hs-CRP Decrease with Dietary Intervention with Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial 2015 · Active treatment · Adults aged 70–88 years from an elderly Swedish community population; no condition required for inclusion | 200 mg | 1461 days | 221 |
| Significant Changes in Metabolic Profiles after Intervention with Selenium and Coenzyme Q10 in an Elderly Population 2019 · SeQ10 active treatment group · Men aged 70–88 from a healthy elderly community-living population | 200 mg | 4 years | 221 |
| Effects of an Intervention with Selenium and Coenzyme Q(10) on Five Selected Age-Related Biomarkers in Elderly Swedes Low in Selenium: Results That Point to an Anti-Ageing Effect-A Sub-Analysis of a Previous Prospective Double-Blind Placebo-Controlled Randomised Clinical Trial 2023 · Active treatment · Elderly community-dwelling Swedes with low selenium status; age range not stated at intervention | 200 mg | 1461 days | 220 |
| Effects of EPA, γ-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial 2013 · group 3 (CoQ10) · Healthy men with serum PSA ≤ 2.5 ng/ml | 400 mg | 12 weeks | 126 |
| Decreased Concentration of Fibroblast Growth Factor 23 (FGF-23) as a Result of Supplementation with Selenium and Coenzyme Q(10) in an Elderly Swedish Population: A Sub-Analysis 2022 · active treatment group · Swedish adults aged 70–88 with low selenium status | 200 mg | 1461 days | 118 |
| Selenium and Coenzyme Q10 Supplementation Improves Renal Function in Elderly Deficient in Selenium: Observational Results and Results from a Subgroup Analysis of a Prospective Randomised Double-Blind Placebo-Controlled Trial 2020 · Active supplementation with selenium and coenzyme Q10 · Adults aged 70–88 years with low pre-intervention selenium status, living in the community | 200 mg | 1461 days | 117 |
| Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men 2009 · group 1 · Infertile men with idiopathic oligoasthenoteratospermia | 300 mg | 26 weeks | 106 |
| Dietary Supplementation with Selenium and Coenzyme Q(10) Prevents Increase in Plasma D-Dimer While Lowering Cardiovascular Mortality in an Elderly Swedish Population 2021 · Active treatment · Adults aged 70–88 years living in a Swedish rural community, with suboptimal serum selenium status; the analysed group excluded people with atrial fibrillation or anticoagulant treatment, malignancy, or left atrium dimension over 40 mm. | 200 mg | 4 years | 106 |
| Selenium and Coenzyme Q(10) Intervention Prevents Telomere Attrition, with Association to Reduced Cardiovascular Mortality-Sub-Study of a Randomized Clinical Trial 2022 · active treatment · Adults aged over 69 years living in a rural municipality in Sweden, with low selenium status; elderly population | 200 mg | 4 years | 67 |
| NT-Pro BNP Predicts Myocardial Injury Post-vascular Surgery and is Reduced with CoQ(10): A Randomized Double-Blind Trial 2020 · CoQ 10 · Patients undergoing elective vascular surgery, including patients with cardiovascular risk factors | 400 mg | 3 days | 62 |
| Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial 2011 · CoQ supplement · Patients with ischaemic left ventricular systolic dysfunction | 300 mg | 8 weeks | 28 |
| Significant changes in circulating microRNA by dietary supplementation of selenium and coenzyme Q10 in healthy elderly males. A subgroup analysis of a prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens 2017 · Active treatment · Men aged 70–80 years in a community-based elderly population; some had hypertension or ischemic heart disease, and many had low selenium status | 200 mg | 4 years | 25 |
| Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial 2013 · coenzyme Q10 (Q10-300 group) · Adults with coronary artery disease receiving statin therapy; women were postmenopausal and not receiving hormone therapy. | 300 mg | 12 weeks | 23 |
| Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial 2022 · QP group (coenzyme Q10 plus placebo) · Adults aged 18 years or older with metabolic syndrome; men and women | 60 mg | 12 weeks | 22 |
| Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study 1999 · 90 mg/day Q10 group · Volunteers vaccinated against hepatitis B; age and sex not reported | 90 mg | 90 days | 21 |
| Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure 2005 · CoQ(10) · Adults with stable NYHA class II or III chronic heart failure secondary to ischemic heart disease; mean age 59 years | 300 mg | 4 weeks | 21 |
| Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial 2016 · Q10-300 group · Adults aged 20–80 with primary hepatocellular carcinoma after tumor resection | 300 mg | 12 weeks | 21 |
| The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study 2016 · Ubiquinone · Adults aged 30–75 with type 2 diabetes and non-proliferative diabetic retinopathy | 400 mg | 26 weeks | 20 |
| The effect of ubiquinone and combined antioxidant therapy on oxidative stress markers in non-proliferative diabetic retinopathy: A phase IIa, randomized, double-blind, and placebo-controlled study 2016 · Coenzyme Q10 · Adults with type 2 diabetes and non-proliferative diabetic retinopathy, without macular edema; males and females | 400 mg | 26 weeks | 20 |
| Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress 2015 · 300 mg/day dose period · Adults aged 18–85 with end-stage renal disease receiving maintenance hemodialysis and elevated baseline F2-isoprostanes | 300 mg | 2 weeks | 20 |
| Effect of coenzyme Q10 supplementation on oxidative stress and clinical outcomes in patients with low levels of coenzyme Q10 admitted to the intensive care unit 2021 · Intervention group · Adults aged 18–65 with traumatic injury, sub-therapeutic plasma CoQ10, and expected need for mechanical ventilation and ICU stay | 400 mg | 7 days | 20 |
| Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study 2007 · CoQ(10)-treated group · Adults with coronary artery disease; mean age 55 years; 33 men and 5 women enrolled across the study | 300 mg | 30 days | 19 |
| Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10 2008 · CoQ10 group · Male elite Japanese kendo athletes; age not reported | 300 mg | 20 days | 10 |
| Effect of Short-term Coenzyme Q10 Supplementation and Precooling on Serum Endogenous Antioxidant Enzymes of Elite Swimmers 2018 · CoQ10 · Healthy male elite adolescent swimmers, mean age 17.5 years | 300 mg | 2 weeks | 9 |
| Effect of Short-term Coenzyme Q10 Supplementation and Precooling on Serum Endogenous Antioxidant Enzymes of Elite Swimmers 2018 · Supplementation with precooling · Healthy male elite adolescent swimmers, mean age 17.5 years | 300 mg | 2 weeks | 9 |
| Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle 2002 · CoQ10-treated subjects · Aged individuals receiving CoQ10 before hip replacement surgery; sex and age range not reported | 300 mg | 4 weeks | — |
| Selenium and coenzyme Q(10) improve the systemic redox status while reducing cardiovascular mortality in elderly population-based individuals 2023 · selenium and coenzyme Q10 supplementation · Elderly community-dwelling individuals with low levels of selenium and coenzyme Q10 | 200 mg | 4 years | — |
| Complementary therapy in diabetic patients with chronic complications: a pilot study 2010 · QALAPL group · Patients with diabetes; age and sex not reported | 60 mg | 90 days | 20 |
| Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study 2003 · 30 mg Q10 group · healthy men | 30 mg | 60 days | — |
| Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial 2006 · High-dose, one daily dose · Children with Down syndrome; age range and sex not reported | 10 mg/kg | 60 days | — |
| Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial 2006 · High-dose, split into two daily doses · Children with Down syndrome; age range and sex not reported | 10 mg/kg | 60 days | — |
| Safety assessment of PureSorb-Q40 in healthy subjects and serum coenzyme Q10 level in excessive dosing 2007 · P40 group · Healthy volunteers | 900 mg | 4 weeks | — |
| Bioavailability and Cellular Compatibility of a Novel Coenzyme Q(10) Emulgel as an Alternative Oral Delivery System for Patients with Dysphagia: Preliminary Results from a Randomized Study 2026 · Emulgel, single-dose study · Healthy adults; age and sex not reported | 1 g | 1 day | — |
| Bioavailability and Cellular Compatibility of a Novel Coenzyme Q(10) Emulgel as an Alternative Oral Delivery System for Patients with Dysphagia: Preliminary Results from a Randomized Study 2026 · Solid capsules, single-dose study · Healthy adults; age and sex not reported | 1 g | 1 day | — |
| Coenzyme Q10 mitigates macrophage mediated inflammation in heart following myocardial infarction via the NLRP3/IL1β pathway 2024 · CoQ10 group · adults with myocardial infarction successfully treated with percutaneous coronary intervention | 30 mg | 90 days | 61 |
| Dietary intake of coenzyme Q10 reduces oxidative stress in patients with acute ischemic stroke: a double-blind, randomized placebo-controlled study 2025 · CoQ10 group · Patients hospitalized for acute ischemic stroke; age and sex not specified | 600 mg | 30 days | 25 |
| Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis 2013 · CoQ10 supplement · Patients with relapsing-remitting multiple sclerosis; age and sex not specified | 500 mg | 12 weeks | 24 |
| Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial 2015 · Coenzyme Q10-supplemented group · Patients with relapsing-remitting multiple sclerosis; age and sex not stated | 500 mg | 12 weeks | 24 |
| Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial 2022 · CQ group (curcumin plus coenzyme Q10) · Adults aged 18 years or older with metabolic syndrome; men and women | 60 mg | 12 weeks | 22 |
| Complementary therapy in diabetic patients with chronic complications: a pilot study 2010 · QALA group · Patients with diabetes; age and sex not reported | 60 mg | 90 days | 20 |
| Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress 2015 · 600 mg/day dose period · Adults aged 18–85 with end-stage renal disease receiving maintenance hemodialysis and elevated baseline F2-isoprostanes | 600 mg | 2 weeks | 19 |
| Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress 2015 · 1200 mg/day dose period · Adults aged 18–85 with end-stage renal disease receiving maintenance hemodialysis and elevated baseline F2-isoprostanes | 1.2 g | 2 weeks | 18 |
| Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress 2015 · 1800 mg/day dose period · Adults aged 18–85 with end-stage renal disease receiving maintenance hemodialysis and elevated baseline F2-isoprostanes | 1.8 g | 2 weeks | 15 |
| MitoQ supplementation does not impact redox responses to acute exercise in skeletal muscle of older individuals 2025 · MitoQ group · Healthy older men and women, approximately 70 years old, without chronic illness | 20 mg | 12 weeks | 11 |
| Increased serum and low-density-lipoprotein antioxidant potential after antioxidant supplementation in endurance athletes 1997 · antioxidant trial · Eight endurance athletes | 60 mg | 4 weeks | 8 |
| Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures 2012 · CoQ · Adults aged 50–85 with probable Alzheimer disease and MMSE scores of 16 or more | 1.2 g | 16 weeks | — |
| Effect of Coenzyme Q(10) on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ(10) Biomarker Trial 2017 · 600 mg CoQ10 group · Adults aged over 18 and under 85 receiving maintenance hemodialysis | 600 mg | 120 days | — |
| Effect of Coenzyme Q(10) on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ(10) Biomarker Trial 2017 · 1200 mg CoQ10 group · Adults aged over 18 and under 85 receiving maintenance hemodialysis | 1.2 g | 120 days | — |
| Coenzyme Q(10) supplementation reduces oxidative stress and decreases antioxidant enzyme activity in children with autism spectrum disorders 2018 · 30 mg daily group · Children with autism spectrum disorders diagnosed using DSM-IV criteria and assessed with CARS | 30 mg | 100 days | — |
| Women have higher levels of CoQ(10) than men when supplemented with a single dose of CoQ(10) with monoglycerides omega-3 or rice oil and followed for 48 h: a crossover randomised triple blind controlled study 2022 · CoQ10 + MAG-OM3 · Healthy men and women aged 18–50 years | 200 mg | 1 day | 30 |
| Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners 1998 · antioxidant cocktail · Moderately trained male marathon runners | 90 mg | 3 weeks | 18 |
| Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study 2000 · Q10 and d-alpha-tocopherol group · Subjects with mild hypercholesterolemia undergoing statin treatment | 200 mg | 90 days | — |
| Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial 2024 · CoQ10 group · Adults aged 18 years or older with metabolic-dysfunction associated steatotic liver disease and at least one extra cardiometabolic risk factor, without diabetes mellitus | 240 mg | 26 weeks | 30 |
| Comparison of L-Carnitine vs. Coq10 and Vitamin E for idiopathic male infertility: a randomized controlled trial 2022 · control group · men with asthenozoospermia and teratozoospermia | 30 mg | 90 days | 70 |
| Circulating levels of reactive oxygen species in patients with nonproliferative diabetic retinopathy and the influence of antioxidant supplementation: 6-month follow-up 2015 · Group A (antioxidant dietary supplementation) · Adults aged 40–79 with type 2 diabetes and mild or moderate nonproliferative diabetic retinopathy | 20 mg | 26 weeks | 34 |
| Coenzyme Q10 and antioxidants in acute myocardial infarction 1994 · verum group · Patients admitted with acute myocardial infarction and symptom duration under 6 hours | 100 mg | 1 year | 32 |
| n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease 2016 · n-3 fatty acids + CoQ · Men and women aged 25–75 years with chronic renal impairment (eGFR >15 and <60 mL/min/1.73 m²) | 200 mg | 8 weeks | 18 |
| Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy 2007 · Group IV (CoRN for 45 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified | 100 mg | 45 days | — |
| Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy 2007 · Group V (CoRN for 90 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified | 100 mg | 90 days | — |
| Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin 2007 · Group IV (CoRN for 45 days) · Breast cancer patients treated with tamoxifen | 100 mg | 45 days | — |
| Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin 2007 · Group V (CoRN for 90 days) · Breast cancer patients treated with tamoxifen | 100 mg | 90 days | — |
| Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy 2008 · CoRN supplement plus tamoxifen · Breast cancer patients undergoing tamoxifen therapy | 100 mg | — | — |
| Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy 2008 · Group IV (CoRN for 45 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported | 100 mg | 45 days | — |
| Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy 2008 · Group V (CoRN for 90 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported | 100 mg | 90 days | — |
| n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease 2015 · n-3 fatty acids and CoQ · Patients with chronic kidney disease | 200 mg | 8 weeks | — |
| Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia 2017 · third group (statin + omega-3 PUFA + CoQ10) · People with combined dyslipidemia and elevated TAG levels; age and sex not reported | 200 mg | 90 days | — |
| The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease 2018 · n-3 FA plus CoQ · Patients with chronic kidney disease (CKD) | 200 mg | 8 weeks | — |
| Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial 2014 · Intervention (Armolipid Plus/AP) · Men and women older than 18 years with mild-moderate hypercholesterolemia and elevated LDL-c, candidates for lifestyle intervention without hypolipemic drug treatment | 2 mg | 12 weeks | 51 |
| Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial 2017 · Active nutraceutical · Adults aged 25–75 with moderately elevated cholesterol and metabolic syndrome, in primary cardiovascular prevention | 50 mg | 6 weeks | 30 |
| The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial 2019 · Multinutrient supplementation group · Women aged 19–35 with polycystic ovary syndrome (PCOS) | 30 mg | 90 days | 30 |
| Dietary intervention with a specific micronutrient combination for the treatment of patients with cardiac arrhythmias: the impact on insulin resistance and left ventricular function 2018 · verum group · Adults aged 18–75 with cardiac arrhythmias (ventricular or supraventricular premature beats or supraventricular tachycardia); patients with cardiovascular disorders, often including hypertension or coronary artery disease | 60 mg | 6 weeks | 29 |
| Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial 2019 · Nutraceutical B · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded. | 2 mg | 6 weeks | 23 |
| Effects of a Combination of Water-Soluble CoenzymeQ10 and Collagen on Skin Parameters and Condition:Results of a Randomised, Placebo-Controlled,Double-Blind Study 2020 · test group · Healthy Caucasian women aged 40–65 with signs of skin aging | 50 mg | 12 weeks | 17 |
| Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants 1997 · antioxidants · male smokers with combined hyperlipidemia | 30 mg | 6 weeks | — |
| Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants 1997 · omega-3 FAs and antioxidants · male smokers with combined hyperlipidemia | 30 mg | 6 weeks | — |
| A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease 2016 · n-3 fatty acids and Coenzyme Q10 · Patients with chronic kidney disease; age and sex not specified. | 200 mg | 8 weeks | — |